| 317.97 -3.575 (-1.11%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 388.93 |
1-year : | 454.27 |
| Resists | First : | 332.98 |
Second : | 388.93 |
| Pivot price | 306.22 |
|||
| Supports | First : | 303.37 |
Second : | 285.07 |
| MAs | MA(5) : | 312.68 |
MA(20) : | 304.55 |
| MA(100) : | 277.09 |
MA(250) : | 221.3 |
|
| MACD | MACD : | 6.8 |
Signal : | 6.3 |
| %K %D | K(14,3) : | 78.4  |
D(3) : | 77.3 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 332.98 | Low : | 127.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KRYS ] has closed below upper band by 10.1%. Bollinger Bands are 10.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 333.26 - 334.94 | 334.94 - 336.02 |
| Low: | 312.62 - 314.8 | 314.8 - 316.19 |
| Close: | 314.85 - 318.13 | 318.13 - 320.23 |
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Thu, 11 Jun 2026
Krystal Biotech, Inc. (KRYS) tops Q1 earnings and revenue estimates - MSN
Tue, 09 Jun 2026
This Insider Has Just Sold Shares In Krystal Biotech - simplywall.st
Sun, 07 Jun 2026
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now? - Yahoo Finance
Sat, 06 Jun 2026
Should Strong Vyjuvek Earnings And Analyst Optimism Require Action From Krystal Biotech (KRYS) Investors? - Sahm
Fri, 05 Jun 2026
Krystal Biotech (KRYS) CEO trades 25,000 shares under 10b5-1 plan - Stock Titan
Fri, 05 Jun 2026
Is the Options Market Predicting a Spike in Krystal Biotech Stock? - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 11.1 (%) |
| Held by Institutions | 99.4 (%) |
| Shares Short | 3,180 (K) |
| Shares Short P.Month | 2,910 (K) |
| EPS | 7.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 43.36 |
| Profit Margin | 53.9 % |
| Operating Margin | 46.1 % |
| Return on Assets (ttm) | 9 % |
| Return on Equity (ttm) | 19.8 % |
| Qtrly Rev. Growth | 31.8 % |
| Gross Profit (p.s.) | 13.32 |
| Sales Per Share | 14.15 |
| EBITDA (p.s.) | 6.12 |
| Qtrly Earnings Growth | 52.5 % |
| Operating Cash Flow | 250 (M) |
| Levered Free Cash Flow | 137 (M) |
| PE Ratio | 42.62 |
| PEG Ratio | 0 |
| Price to Book value | 7.33 |
| Price to Sales | 22.46 |
| Price to Cash Flow | 37.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|